Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-20T09:38:42.087Z Has data issue: false hasContentIssue false
  • English
  • Français

A double-blind placebo-controlled multicentre study of sertraline in the acute and continuation treatment of major depression

Published online by Cambridge University Press:  16 April 2020

JP Olie ,
KP Gunn  and
E Katz
JP Olie
Affiliation:
Hospital Saint-Anne, Paris, France
KP Gunn*
Affiliation:
Pfizer Central Research, Ramsgate Road, Sandwich, KentCT13 9NJ, UK
E Katz
Affiliation:
Pfizer Central Research, Paris, France
*
*Correspondence and reprints.
Get access

Summary

In a double-blind multicentre study of outpatients with DSM-III-R major depressive disorder, 129 sertraline and 129 placebo patients were evaluated over a 6-week period. Sertraline exhibited a significantly greater (P < 0.001) antidepressant effect compared to placebo as measured by the HAM-D, MADRS, CGI-S and CGI-I. In the subset of patients with severe depression (baseline HAM-D ≥ 25), sertraline was also significantly more effective than placebo (P < 0.05). Side effects were more commonly reported in sertraline (59%) compared to placebo (38%) patients; the most common being nausea, headache and insomnia. A subset of 107 patients (66 sertraline; 41 placebo) who were defined as responders (CGI-I of 1 or 2) after 6 weeks treatment were entered into a 20-week continuation phase. In this responder subset, there was continuing improvement in both groups of patients, but with no significant differences in mean HAM-D or MADRS between the groups. However, a higher number of sertraline patients were associated with a persistent pattern of improvement relative to placebo (P < 0.05). The incidence of side effects was similar in sertraline (52%) and placebo (49%) treated patients in the continuation period.

Keywords

SSRIsertralinemajor depression
Type
Original article
Information
European Psychiatry , Volume 12 , Issue 1 , 1997 , pp. 34 - 41

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association Third EditionDiagnostic and Statistical Manual of Mental Disorders. New York: The American Psychiatric Association, 1987Google Scholar
Bersani, G, Rapisarda, V, Ciani, N, Bertolini, A, Sorge, G. A double-blind comparative study of sertraline and amitriptyline in outpatients with major depressive episodes. Hum Psychopharmacol 1994; 9: 63–68CrossRefGoogle Scholar
Benfield, P, Heel, RC, Lewis, SP. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness. Drugs 1986; 32: 481–508CrossRefGoogle ScholarPubMed
Cohn, CK, Shrivastava, R, Mendels, J, et al.Double-blind, multi-centre comparison of sertraline and amitriptyline in elderly depressed patients J Clin Psychiatry 51suppl B1990 28–33Google Scholar
Coppen, AJ, Mendelwicz, J, Kielholz, PPharmacotherapy of Depressive Disorders: A Consensus Statement. Geneva: World Health Organisation, 1986Google Scholar
Doogan, DP, Caillard, V. Sertraline: A new antidepressant J Clin Psychiatry 4981988 46–51Google ScholarPubMed
Doogan, DP, Caillard, V. Sertraline in the prevention of depression. Br J Psychiatry 1992; 160: 217–222CrossRefGoogle ScholarPubMed
Doogan, DP, Langdon, CJ. A double-blind placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice. Int Clin Psychopharmacol 1994; 9: 95–100CrossRefGoogle ScholarPubMed
Fabre, LF, Abuzzahab, FS, Amin, M, et al.Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry 1995; 38: 592–692CrossRefGoogle ScholarPubMed
Grimsley, SR, Jann, MW. Paroxetine, sertraline and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm 1992; 11: 930–957Google ScholarPubMed
Guy, WClinical Global ImpressionsECDEU Manual NIMH Rockville, Maryland: US Dept. of Health and Human Services, 1976; 217–222Google Scholar
Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62CrossRefGoogle ScholarPubMed
Johnson, AMSelective Serotonin Reuptake InhibitorsBryer, WF, Feighner, JFProgress in Psychiatry vol I New York: John Wiley, 1991; 37–70Google Scholar
Keller, MB, Klerman, GL, Lavori, PW, et al.Treatment received by depressed patients. JAMA 1992; 248: 1848–1855CrossRefGoogle Scholar
Koe, BK, Weissman, A, Welch, WM, Browne, RG. Sertraline: A new selective inhibitor of serotonin uptake Psychopharmacol Bull 1941983 687–691Google Scholar
Montgomery, A, Asberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–389CrossRefGoogle ScholarPubMed
Montgomery, SA. Prophylaxis in recurrent unipolar depression: a new indication for treatment studies J Psychopharmacol 321989 47–53CrossRefGoogle ScholarPubMed
Montgomery, SA, Doogan, DP, Burnside, R. The influence of different relapse criteria on the assessment of long term efficacy of sertraline Int Clin Psychopharmacol 621991 37–46CrossRefGoogle ScholarPubMed
Preskorn, SH, Lane, R. Sertraline 50mg daily — the optimal dose in the treatment of depression Int Clin Psychopharmacol 91031995Google Scholar
Murdoch, D, McTavish, D. Sertraline: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compliance disorder Drugs 4441992 604–624CrossRefGoogle ScholarPubMed
Quitkin, F, Rabkin, JD, Markowicz, JM, et al.Use of pattern analysis to identify true drug response Arch Gen Psychiatry 4431987 259–264CrossRefGoogle ScholarPubMed
Quitkin, F, Burnside, R, Yurkewicz, . Positive pattern analysis results in sertraline depression trials Presented at XVIII CINP Nice, France 28 June–2 July 1992Google Scholar
Reimherr, FW, Chouinard, G, Cohn, CK, et al.Antidepressant efficacy of sertraline: A double-blind, placebo-and -amitriptyline-controlled, multicenter comparison study in outpatients with major depressio J Clin Psychiatry 12suppl B1990 18–27Google Scholar
Rickels, K, Schweizer, E. Clinical overview of serotonin reuptake inhibitors J Clin Psychiatry 51suppl B1990 9–12Google ScholarPubMed
Shopsin, B, Cassano, GB, Conti, LAn Overview of New ‘Second Generation’ Antidepressants: Neurochemical, Behavioural and Clinical Perspectives Enna, J, Malick, JB, Richelson, ENew York: Raven Press, 1981Google Scholar
Thompson, C. Management of depression in real-life settings: knowledge gained from large-scale trials Int Clin Psychopharmacol 931994 21–25CrossRefGoogle Scholar
Woggan, B. Methodology of measuring the efficacy of antidepressants — European viewpoint. Psychopharmacology 1992; 106: 590–592Google Scholar
Submit a response

Comments

No Comments have been published for this article.